Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.
Hu C, Wang A, Wu H, Qi Z, Li X, Yan XE, Chen C, Yu K, Zou F, Wang W, Wang W, Wu J, Liu J, Wang B, Wang L, Ren T, Zhang S, Yun CH, Liu J, Liu Q.
Hu C, et al. Among authors: wang w, wang l, wang b, wang a.
Oncotarget. 2017 Mar 14;8(11):18359-18372. doi: 10.18632/oncotarget.15443.
Oncotarget. 2017.
PMID: 28407693
Free PMC article.